From the Department of Internal Medicine, Section of Molecular Medicine (A.C.B., M.L., C-C.C.K., E.B., X.W., J.K.S., J.S.P.), Wake Forest School of Medicine, Winston-Salem, NC.
Department of Internal Medicine, Section on Gerontology and Geriatric Medicine (C.M.C., S.L.M.), Wake Forest School of Medicine, Winston-Salem, NC.
Arterioscler Thromb Vasc Biol. 2019 Sep;39(9):1747-1761. doi: 10.1161/ATVBAHA.119.312382. Epub 2019 Jun 6.
The role of hepatocyte Abca1 (ATP binding cassette transporter A1) in trafficking hepatic free cholesterol (FC) into plasma versus bile for reverse cholesterol transport (RCT) is poorly understood. We hypothesized that hepatocyte Abca1 recycles plasma HDL-C (high-density lipoprotein cholesterol) taken up by the liver back into plasma, maintaining the plasma HDL-C pool, and decreasing HDL-mediated RCT into feces. Approach and Results: Chow-fed hepatocyte-specific Abca1 knockout (HSKO) and control mice were injected with human HDL radiolabeled with I-tyramine cellobiose (I-TC; protein) and H-cholesteryl oleate (H-CO). I-TC and H-CO plasma decay, plasma HDL H-CO selective clearance (ie, H-I fractional catabolic rate), liver radiolabel uptake, and fecal H-sterol were significantly greater in HSKO versus control mice, supporting increased plasma HDL RCT. Twenty-four hours after H-CO-HDL injection, HSKO mice had reduced total hepatic H-FC (ie, H-CO hydrolyzed to H-FC in liver) resecretion into plasma, demonstrating Abca1 recycled HDL-derived hepatic H-FC back into plasma. Despite similar liver LDLr (low-density lipoprotein receptor) expression between genotypes, HSKO mice treated with LDLr-targeting versus control antisense oligonucleotide had slower plasma H-CO-HDL decay, reduced selective H-CO clearance, and decreased fecal H-sterol excretion that was indistinguishable from control mice. Increased RCT in HSKO mice was selective for H-CO-HDL, since macrophage RCT was similar between genotypes.
Hepatocyte Abca1 deletion unmasks a novel and selective FC trafficking pathway that requires LDLr expression, accelerating plasma HDL-selective CE uptake by the liver and promoting HDL RCT into feces, consequently reducing HDL-derived hepatic FC recycling into plasma.
肝细胞 Abca1(ATP 结合盒转运体 A1)在将肝脏游离胆固醇(FC)转运到血浆中以进行胆固醇逆向转运(RCT)方面的作用尚未完全清楚。我们假设肝细胞 Abca1 会将肝脏摄取的血浆高密度脂蛋白胆固醇(HDL-C)循环回血浆中,维持血浆 HDL-C 池,并减少 HDL 介导的 RCT 进入粪便。
给予常规饮食的肝细胞特异性 Abca1 敲除(HSKO)和对照小鼠注射用 I-酪胺纤维二糖(I-TC;蛋白)放射性标记的人 HDL 和 H-油酰胆固醇(H-CO)。I-TC 和 H-CO 血浆衰减、血浆 HDL H-CO 选择性清除率(即 H-I 分数代谢率)、肝脏放射性标记摄取和粪便 H-甾醇在 HSKO 与对照小鼠之间显著增加,支持增加的血浆 HDL RCT。在 H-CO-HDL 注射后 24 小时,HSKO 小鼠总肝 H-FC(即 H-CO 在肝脏中水解为 H-FC)重新分泌到血浆中的量减少,表明 Abca1 将 HDL 衍生的肝 H-FC 循环回血浆。尽管两种基因型的肝脏 LDLr(低密度脂蛋白受体)表达相似,但用 LDLr 靶向与对照反义寡核苷酸处理的 HSKO 小鼠的血浆 H-CO-HDL 衰减更慢,选择性 H-CO 清除率降低,粪便 H-甾醇排泄减少,与对照小鼠无明显差异。HSKO 小鼠的 RCT 增加是选择性的,因为两种基因型之间的巨噬细胞 RCT 相似。
肝细胞 Abca1 缺失揭示了一种新的和选择性的 FC 转运途径,该途径需要 LDLr 表达,加速肝脏对血浆 HDL-CE 的选择性摄取,并促进 HDL 进入粪便的 RCT,从而减少 HDL 衍生的肝 FC 循环回血浆。